BR112017026291A2 - dispersões sólidas, formulações farmacêuticas ou nutracêuticas e método para preparar uma dispersão sólida - Google Patents

dispersões sólidas, formulações farmacêuticas ou nutracêuticas e método para preparar uma dispersão sólida

Info

Publication number
BR112017026291A2
BR112017026291A2 BR112017026291-6A BR112017026291A BR112017026291A2 BR 112017026291 A2 BR112017026291 A2 BR 112017026291A2 BR 112017026291 A BR112017026291 A BR 112017026291A BR 112017026291 A2 BR112017026291 A2 BR 112017026291A2
Authority
BR
Brazil
Prior art keywords
solid
pharmaceutical
preparing
solid dispersion
nutraceutical formulations
Prior art date
Application number
BR112017026291-6A
Other languages
English (en)
Other versions
BR112017026291B1 (pt
Inventor
Ciceri Daniele
PETERLONGO Federico
Ronchi Massimo
Original Assignee
Indena S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena S.P.A filed Critical Indena S.P.A
Publication of BR112017026291A2 publication Critical patent/BR112017026291A2/pt
Publication of BR112017026291B1 publication Critical patent/BR112017026291B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)

Abstract

a presente invenção se refere a uma dispersão sólida que compreende a coenzima q10 e um fosfolipídeo, na presença de um derivado celulósico e/ou um material polimérico selecionado a partir do grupo que consiste de polivinilpirrolidona, acetato de polivinila, ácido polimetacrílico, metacrilato de polimetila, poloxâmeros, quitosana, alginatos, ácido hialurônico, pectina, pululana, ciclodextrinas, polímeros de amido e succinato de d-alfa-tocoferil-polietilenoglicol 1000.
BR112017026291-6A 2015-06-12 2016-06-10 Dispersões sólidas, formulações farmacêuticas ou nutracêuticas e método para preparar uma dispersão sólida BR112017026291B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15171943.2A EP3103440A1 (en) 2015-06-12 2015-06-12 Solid dispersions of coenzyme q10
EP15171943.2 2015-06-12
PCT/EP2016/063262 WO2016198576A1 (en) 2015-06-12 2016-06-10 Solid dispersions of coenzyme q10

Publications (2)

Publication Number Publication Date
BR112017026291A2 true BR112017026291A2 (pt) 2018-09-11
BR112017026291B1 BR112017026291B1 (pt) 2023-08-22

Family

ID=

Also Published As

Publication number Publication date
CN107750158A (zh) 2018-03-02
WO2016198576A1 (en) 2016-12-15
HK1250652A1 (zh) 2019-01-11
IL256159A (en) 2018-02-28
CA2988478C (en) 2023-10-03
PT3307244T (pt) 2020-02-03
EP3307244A1 (en) 2018-04-18
ES2768950T3 (es) 2020-06-24
EP3307244B1 (en) 2019-11-20
RU2017142563A3 (pt) 2019-11-28
EP3103440A1 (en) 2016-12-14
JP2018516945A (ja) 2018-06-28
US10905657B2 (en) 2021-02-02
RU2017142563A (ru) 2019-07-12
AU2016274662B2 (en) 2020-08-20
JP6910309B2 (ja) 2021-07-28
KR20180017016A (ko) 2018-02-20
CA2988478A1 (en) 2016-12-15
DK3307244T3 (da) 2020-02-24
RU2742579C2 (ru) 2021-02-08
CN107750158B (zh) 2021-08-27
HUE047668T2 (hu) 2020-05-28
US20180200201A1 (en) 2018-07-19
SI3307244T1 (sl) 2020-03-31
PL3307244T3 (pl) 2020-05-18
AU2016274662A1 (en) 2018-01-04
IL256159B (en) 2020-06-30

Similar Documents

Publication Publication Date Title
WO2013105101A8 (en) Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same
BR112018010683B8 (pt) Método para produzir uma composição de glucano
MX2023006541A (es) Formulaciones de dosis fija.
PH12015501486A1 (en) Nanoparticle compositions of albumin and paclitaxel
JP2012140433A5 (pt)
BR112014029247A2 (pt) nanopartícula de lipídio, composição farmacêutica, método para fazer uma nanopartícula de lipído, produto, método de tratamento de um distúrbio, e sistema de entrega
AR082384A1 (es) Particulas
BR112013000675A2 (pt) nanopartícula, processo para produzir uma nanopartícula compreendendo uma matriz de zeína e um aminoácido básico, processo para produzir uma nanopartícula compreendendo uma matriz de zeína, e um aminoácido básico e um composto biologicamente ativo solúvel em gordura, composição e produto alimentar
EP3020733A4 (en) Core-shell crosslinked hyaluronic acid gel particles, production method for same, and medical material
BR112014029286A2 (pt) composição cosmética sólida, processo para sua produção, produto e método cosmético
EP3241546A4 (en) Polymer nanoparticle freeze-dried product, and preparation method therefor
CO2017012573A2 (es) Formación de nanopartículas de ciclosporina a/ciclodextrina
ES2570902T3 (es) Producto acuoso que comprende microcápsulas que contienen aceite y un procedimiento de fabricación del mismo
WO2014198683A3 (en) Compositions comprising cross-linked hyaluronic acid and cyclodextrin
PH12015502556A1 (en) Modified release formulation
BR112017001207A2 (pt) método para moldar um corpo em um molde
BR112014032583A8 (pt) forma farmacêutica para liberação prolongada de substâncias ativas e seu processo de produção
BR112017022523A2 (pt) ?formulação para cápsulas de gel, cápsula de gel, e, processo?.
BR112018010066A8 (pt) Agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo
BR112012029171A2 (pt) composição farmacêutica de ibruprofeno para injeção
BR112019007001A2 (pt) estrutura fibrosa, produto de papel tissue, e, método de fabricação de uma manta de papel tissue com um odor semelhante a limão.
BR112017026291A2 (pt) dispersões sólidas, formulações farmacêuticas ou nutracêuticas e método para preparar uma dispersão sólida
MX2018008888A (es) Polimeros a base de ciclodextrina, metodos, composiciones y aplicaciones de los mismos.
MD4546B9 (ro) Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron
BR112014031267A2 (pt) processo de preparação de objetos de hidrogel biocompatível para suas aplicações no campo médico, e mais particularmente em oftalmologia.

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: DE ACORDO COM COMUNICADO PUBLICADO NA RPI 2526 DE 04/06/2019 FICAM DEVOLVIDOS DE 11/06/2019 ATE 14/06/2019 OS PRAZOS VENCIDOS NAS DATAS DIVULGADAS DENTRO DO COMUNICADO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/06/2016, OBSERVADAS AS CONDICOES LEGAIS